All advisors agreed that genetic testing to identify GLA gene variants and blood tests measuring activity of α-Gal A enzyme and lyso-GL3 concentrations are key examinations used to aid the diagnosis of FD in all patients. This evidence concerns the gene GLA and Fabry disease.